Tonix Pharmaceuticals Holding Corp. (TNXP)

US — Healthcare Sector

Peers: SONN ONTX PALI IBIO JAGX ACST DFFN VXRT VBIV DRUG VRAX NVAX INO ENVB CWBR

Automate Your Wheel Strategy on TNXP

With Tiblio's Option Bot, you can configure your own wheel strategy including TNXP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol TNXP
Rev/Share 1.694
Book/Share 30.4351
PB 1.307
Debt/Equity 0.0031
CurrentRatio 12.3146
ROIC -0.4005

MktCap 291375373.0
FreeCF/Share -10.1138
PFCF -4.8605
PE -2.0486
Debt/Assets 0.0029
DivYield 0
ROE -1.0553

Rating B-
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 4
D/E Score 4

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

TNXP
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals participated in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase.

image for news Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

TNXP
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

CHATHAM, N.J., March 27, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D.

image for news Tonix Pharmaceuticals Announces Presentation at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years

TNXP
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Negative

PDUFA date of August 15th of 2025 set to review on whether or not TNX-102 SL should be approved to treat patients with Fibromyalgia. The company announced that the FDA will not require an Advisory Committee Meeting of TNX-102 SL for the treatment of patients with Fibromyalgia. TNX-102 SL met primary endpoints in two Phase 3 studies, showing significant pain reduction, positioning it as the first new Fibromyalgia drug in 15 years.

image for news Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

TNXP
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Commercial planning for TNX-102 SL underway for launch in the fourth quarter of 2025 CHATHAM, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the U.S. Food and Drug Administration (FDA) will not require an Advisory Committee meeting to discuss the Company's …

image for news Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

TNXP
Published: March 20, 2025 by: Accesswire
Sentiment: Neutral

Clade I, the culprit in the current 2025 version of global epidemic mpox, is highly transmissible and is spreading within families and among children, whereas the 2022 Clade II mpox - still spreading - infects mostly gay men CHATHAM, NJ / ACCESS Newswire / March 20, 2025 / This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of …

image for news As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread

About Tonix Pharmaceuticals Holding Corp. (TNXP)

IPO Date 2012-05-10
Website https://www.tonixpharma.com
Industry Biotechnology
CEO Dr. Seth Lederman M.D.
Employees 81

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.